Key terms
About AURA
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AURA news
Apr 15
4:22pm ET
Raj Parekh to Exit Board at Aura Biosciences’ Meeting
Mar 29
4:53am ET
3 Best Stocks to Buy Now, 3/29/2024, According to Top Analysts
Mar 29
3:07am ET
Aura Biosciences Inc: A Buy Rating on Strong Pipeline and Financial Health
Mar 28
8:40am ET
Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Molina Healthcare (MOH) and Aura Biosciences Inc (AURA)
Mar 28
6:40am ET
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Spectral AI (MDAI) and Pyxis Oncology (PYXS)
Mar 27
3:40pm ET
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Altimmune (ALT)
Mar 27
1:05pm ET
Aura Biosciences: A Strong Buy on Clinical Progress and Financial Stability
Mar 27
8:14am ET
Aura Biosciences files $350M mixed securities shelf
No recent press releases are available for AURA
AURA Financials
Key terms
Ad Feedback
AURA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AURA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
